Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Possible Impact Of Recently Reported Fractures On The Use Of Alendronate

July 18, 2008

Analysis of:Drugs to Build Bones May Weaken Them | www.nytimes.com

1. This study may not have a big impact on the prescriptions of alendronate in the short term unless this problem is found to be more wide-spread. With the increased incidence of jaw necrosis reported earlier, physicians will carefully weigh the benefits before starting alendronate. 2. The fractures were found to be in patients who had taken alendronate for an average of 6.9 years. Physicians may consider stopping the medication after 5 years of use as most of the efficacy is seen in the earlier years of treatment anyway. 3. This type of fracture was identified only with the use of alendronate and not the other bisphosphonates. Physicians may choose to use the other medications rather than alendronate.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS